Get Started

The Aesthetic Show

Join Sensus Healthcare at The Aesthetic Show in Las Vegas, NV July 5th - 8th, 2018. For tickets and more information click here.

Join Sensus Healthcare at the 2018 ASMS - American Society for Mohs Surgery Annual Meeting: Focus on Skin Cancer in Orlando, FL May 24th-27th, 2018. For tickets and more information click here.

Join Sensus Healthcare at the 2018 Texas Dermatological Society Users Meeting in Austin, TX April 27-28, 2018. For tickets and more information click here.

Join Sensus Healthcare at the 2018 ASLMS conference in Dallas, TX April 11-15, 2018. Come and meet the new Sensus Laser Systems. Click here to register today!

Sensus Healthcare will be at the 2018 South Beach Symposium. The event takes place in Miami Beach, FL March 1-4, 2018. Contact us today to schedule your demo at (561) 922-5808 x114. We look forward to seeing you there.

Sensus Healthcare will be at the 2018 AAD Annual Meeting. The event takes place in San Diego, CA February 16 - 20, 2018.

Come by and visit is at booth #4407. Contact us today to schedule your demo at (561) 922-5808 x114. We look forward to seeing you there.

BOCA RATON, Fla. – July 19, 2017Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions, such as keloids with Superficial Radiation Therapy (SRT), announced that the Company will be exhibiting at the 2017 American Association of Physicists in Medicine (AAPM) Annual Meeting in Denver, Colo., on July 30 through August 3.

At AAPM, Sensus will share information about its premier product for radiation oncologists: the SRT-100 Vision, which utilizes the Company’s proprietary, low-energy X-ray radiation technology to effectively, painlessly and safely treat oncological and non-oncological skin conditions. The device delivers precise, calibrated SRT doses while offering high-frequency ultrasound for imaging that allows physicians to create the most effective treatment plans possible for patients, as well as better examine how the lesion is shrinking over time. It also records each session for the patient’s records via the LesionCamTM.

“As the first doctor in Colorado to use SRT, and having used the technology regularly for the past 18+ months, I can tell you that this alternative treatment to surgery is not only highly effective and non-invasive but also perfect for patients who are surgically fatigued from multiple surgeries over time,” said Dr. Kevin Schewe, radiation oncologist at Alliance Cancer Care Colorado at Red Rocks. “SRT provides patients with a treatment option that rivals the effectiveness and cure rate of surgery but requires no scalpels, no needles, and no surgical scars. Sensus Healthcare’s innovative technology has been a tremendous addition to the patient care that we provide.”

“SRT is a game-changer when it comes to treating non-melanoma skin cancer and keloids, and we look forward to connecting with some of the country’s leading radiation oncologists who are in attendance at AAPM this year to share our knowledge and spread the word,” added Joe Sardano, CEO, Sensus Healthcare. “Both patients and doctors benefit greatly from SRT in that the treatment is painless and doesn’t require anesthesia, cutting or stitching and ultimately improves physician productivity by allowing doctors to treat more patients. It’s a win-win for everyone involved.”

For more information on Sensus Healthcare and the SRT-100 Vision, please visit Booth No. 7045 at AAPM in the Colorado Convention Center.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.

###

Media Contacts:

Caitlin Kasunich / Nick Opich

KCSA Strategic Communications

212-896-1241 / 212-896-1206

[email protected] / [email protected]

 

 

BOCA RATON, Fla., April 27, 2017,/PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), announced today that management will hold a conference call beginning at 4:30 p.m. Eastern Time on Thursday, May 4, 2017, to discuss the financial results for the first quarter of 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

To access the conference call, the dial-in numbers are 1-877-870-4263 (U.S. Toll-Free), 1-412-317-0790 (International) and 1-855-669-9657 (Canada Toll-Free). Please ask the operator to be connected to the Sensus Healthcare call.

Following the conclusion of the conference call, a replay will be available through May 11, 2017, and can be accessed by dialing 1-877-344-7529 (U.S. Toll-Free), 1-412-317-0088 (International), and 1-855-669-9658 (Canada Toll-Free). All listeners should provide the replay passcode 10106354. The call will also be archived on the Company website for a time at https://www.sensushealthcare.com

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For further information, please visit https://www.sensushealthcare.com

Contacts:

Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
[email protected]

SOURCE Sensus Healthcare

Dr. David Goldberg spoke at the 2017 South Beach Symposium conference on how SRT technology has rapidly advanced in the past 30 years and how SRT is an effective way to eradicate tumors while maintaining or improving patients’ quality of life. Below is an excerpt from the article by Healio.com covering this presentation:

MIAMI — Superficial radiation therapy, or SRT, offers a safe, effective and cosmetically beneficial alternative to Mohs surgery for non-melanoma skin cancer, according to a speaker here.

“Modern SRT technology is so very different from what we all were exposed to 30 years ago,” David J. Goldberg, MD, JD, said at South Beach Symposium 2017. “These machines are small, they fit in the office and my cosmetic patients don’t even know the machine is there.”

To read the full article, click here.

Joe Sardano, Sensus Healthcare CEO, to Participate in CEO Forum on February 11

Sensus Healthcare Medical Advisory Board Members to Host SRT Workshops on February 9

BOCA RATON, Fla., Feb. 7, 2017,/PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that the company will participate in the 2017 South Beach Symposium (SBS) at the Loews Miami Beach Hotel in Miami Beach, Fla., on February 912.

On February 11 at 4:30 p.m. ET, Joe Sardano, Sensus Healthcare CEO, will participate in the Annual South Beach Symposium Industry CEO Forum to discuss "The Future of Innovation in Dermatology and Aesthetics in an Era of Healthcare Upheaval." Joe will join prominent leaders and colleagues from the industry, including Doug Abel, Sinclair U.S. CEO; Miles Harrison, Galderma Laboratories President, and General Manager; Eduardo Sanchiz, Almirall CEO; Ann Smith, Ferndale Healthcare President, and CEO, and Neal Walker, DO, Aclaris Therapeutics President and CEO.

"It is an honor to participate in the Annual South Beach Symposium Industry CEO Forum," said Sardano. "Every year, we look forward to attending this prominent industry event to showcase our innovative SRT technology. It's an exciting opportunity to represent Sensus among a collection of industry leaders and participate in the discussion on the future of innovation in dermatology and aesthetics. Our proprietary SRT technology for the treatment of non-melanoma skin cancers and keloids is already complementing the industry as it progresses into the future."

Sensus Healthcare Medical Advisory Board Members will also host various SRT panel discussions throughout the day on February 9. Drs. Mark Nestor, MD, Ph.D. and South Beach Symposium founder; David Goldberg, MD, JD; Clay Cockerell, MD; Brian Berman, MD, Ph.D., and William I. Roth, MD, will discuss a variety of SRT topics – ranging from a certification course for dermatology to an introduction/literature review on SRT for treating non-melanoma skin cancer specifically. In addition, an abstract that was co-authored by Dr. George Schmieder, DO, FAOCD, FAAD, will be presented as a poster at the SBS, on the topic of keloid SRT treatment. Schmieder uses the Sensus technology to treat patients at his practice in Orange Park, Fla.

"Given the high incidence of skin cancer which will affect one in five Americans patients are consulting their Dermatologists for new treatment options. SRT represents a highly effective, safe, non-invasive alternative to surgery," said Dr. Mark Nestor, MD, Ph.D. "The Sensus Medical Advisory Board Members understand how this revolutionary SRT technology can benefit their patients. The educational sessions at the Symposium will highlight the benefits of SRT, as well as the importance of getting the word out to patients in need all over the world."

The South Beach Symposium is an annual four-day event that gathers medical professionals to deliver educational content on the newest therapies, technologies, procedures and practice guidelines for physicians and practitioners in the dermatology and aesthetic medicine fields. SBS offers multiple educational tracks that allow medical professionals from both clinical and aesthetic dermatology practices to participate in focused education through the track of their choice.

For more information or to register, please visit the South Beach Symposium website.

About Sensus Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.

Public Relations: Caitlin Kasunich / Nick Opich KCSA Strategic Communications Phone: 212-896-1241 / 212-896-1206 Email: [email protected] / [email protected]

Investor Relations: Kim Golodetz LHA Investor Relations Phone: 212-838-3777 Email: [email protected]

SOURCE Sensus Healthcare

Related Links

https://www.sensushealthcare.com

August 31, 2016

Boca Raton, FL

Sensus Healthcare (SRTSU) To Sponsor First International Keloid Symposium On September 8 And 9 In New York

Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that the Company will sponsor the First International Keloid Symposium to be held at The Rockefeller University in New York on Thursday, September 8th and Friday, September 9th.

The First International Keloid Symposium is a not for profit two-day event organized to bring together industry doctors and scientists to provide a unique environment for collaboration on better practices in the diagnosis, prevention, and treatment of keloid disease. Registered attendees consist of industry experts in basic science, dermatopathology, specialist clinicians with an interest in keloid scars from dermatology, plastic surgery, oncology, pediatric and general surgery, ENT, maxillofacial as well as specialist nurses, physiotherapists, occupational therapists, and psychologists.

"We are thrilled to be the platinum sponsor of the First International Keloid Symposium being held at The Rockefeller University in New York City," said Joe Sardano, Chief Executive Officer for Sensus Healthcare. "Keloid disease is an underserved market that we have a keen interest in helping to address with our SRT devices. It is exciting to display our innovative technology in a unique environment of international thought leaders and practitioners in the industry."

Through its sponsorship program, the Symposium is also bringing products, services, and devices (existing or in development) to display their solutions in front of leading industry professionals. The Symposium will emphasize both the scientific and clinical content across the breadth of keloid scars; highlighting cutting edge basic science research to pros and cons of current and newly emerging treatment approaches including surgical management, cryotherapy, electrotherapy, chemotherapy, and other interventions.

For more information and registration, please visit the event website: keloidsymposium.com

About Sensus
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100 and SRT-100 Vision. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit us here.


Investor Relations:
Kim Golodetz
LHA Investor Relations
Phone: 212-838-3777
Email:
[email protected]

View the original version on PR Newswire here

SOURCE Sensus Healthcare


June 10, 2015

Boca Raton, FL

Leading Dermatologist Dr. Clay J. Cockerell Hosts Educational Event Chaired by Dr. Mark Nestor, President of ACOS

The American Cutaneous Oncology Society (ACOS) brought together nearly 100 dermatologists to share the science and best practices of providing Superficial Radiation Therapy (SRT) to patients with non-melanoma skin cancer (NMSC). The first annual physicians meeting, recently held in Dallas, Texas, featured a two-day CME accredited program geared toward increased knowledge and successful implementation of non-surgical SRT treatment in clinical practice.

"This peer-to-peer meeting was about exchanging ideas and transforming the quality of care delivered to our patients who want a noninvasive and cost-conscious treatment option for basal and squamous cell cancers and keloids," said Clay J. Cockerell, clinical professor, Dermatology and Pathology at UT Southwestern Medical Center in Dallas and former president of the American Academy of Dermatology.

The educational event focused on:

  • Patient-centric treatment techniques
  • New data on treatment regimens
  • Differentiated benefits of SRT

According to ACOS President Mark Nestor, MD, Ph.D., a renowned dermatologist and director of the Center for Clinical and Cosmetic Research in Miami, "All clinicians want appropriate patients with basal and squamous skin cancers or keloids to have the best possible outcomes. In certain cases that means state-of-the-art SRT treatment that preserves healthy tissue and delivers an extremely high cure rate with excellent cosmetic results."
 
To advance the knowledge of those using SRT in practice and enhance patient care, participants heard presentations and participated in discussions on NMSC epidemiology and histopathology, along with the newest iteration of SRT treatment techniques. The group also had an update on reimbursement, coding, and patient education tools.
 
"The meeting was a great way to learn, in person, from others with different experiences and skill levels about best practices in SRT. Both new and veteran users recognized the high value of this convenient treatment modality and came away from the event with a new appreciation for how far Superficial Radiation Therapy has matured in the past few years," noted Dr. Nestor.

About ACOS

The American Cutaneous Oncology Society was founded to provide education and support multidisciplinary approaches for Dermatologists, Radiation Oncologists and other specialized medical professionals who are actively engaged in the diagnosis, treatment, and prevention of skin cancer and precancerous conditions. The Society develops information and resources to further public knowledge regarding skin cancer diagnosis, treatment, and prevention.

Media Contact:
Nadine Tosk, NDTosk Communications
For Sensus Healthcare
504.453.8344

 

February 22, 2013

Boca Raton, FL

Sensus Healthcare is proud to announce their exhibitor participation in the 71st Annual American Academy of Dermatology Meeting in Miami Beach, FL on March 1-5, 2013. Visit booth #2701to learn more about the advanced SRT-100™ superficial radiotherapy platform, featuring SharpBeam™, it’s unique characteristics and advantages over other NMSC treatment modalities, and how it optimally integrates as a dedicated NMSC treatment solution in the radiation therapy department.
“We cordially invite all AAD attendees to take this opportunity to visit our booth in the upcoming 71st Annual Academy of Dermatology Meeting in Miami Beach, FL and rediscover superficial radiotherapy (SRT) as the optimal radiotherapy solution for treating Non-Melanoma Skin Cancer (NMSC) patients. We are proud to feature our contemporary SRT-100™ superficial radiotherapy platform with the unique SharpBeam™ advantage at the meeting and demonstrate to the attendees how they can better their patients’ outcomes while contributing to the optimization of their practice’s workflow, throughput, and operations.” stated Joe Sardano, President/CEO, Sensus Healthcare.

 

About Sensus Healthcare:

Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists around the world to bring non-melanoma skin cancer treatment to more patients in more settings.

 

Media Contact:
Michelle Verina
Public Relations
561-922-5808 Ext. *100
[email protected]

September 28, 2012

Boca Raton, FL

Sensus Healthcare is pleased to announce its exhibitor participation in the 54th Annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston, MA on October 28 - 31, 2012. Visit Booth #9054 to learn more about the advanced SRT-100™ superficial radiotherapy platform, it’s unique characteristics and advantages over other NMSC treatment modalities, and how it optimally integrates as a dedicated NMSC treatment solution in the radiation therapy department.

“We cordially invite all ASTRO attendees to take this opportunity to visit our booth in the upcoming 54th Annual ASTRO meeting in Boston, MA and rediscover superficial radiotherapy (SRT) as the optimal radiotherapy solution for treating Non-Melanoma Skin Cancer (NMSC) patients. We are proud to feature our contemporary SRT-100™ superficial radiotherapy platform at the meeting and demonstrate to the attendees how they can better their patients’ outcomes while contributing to the optimization of their department’s workflow, throughput, and operations.” stated Joe Sardano, President/CEO, Sensus Healthcare.

 

About Sensus Healthcare:

Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. SRT-100™ is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam™ characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100™ is FDA, CE, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.

 

Media Contact:
Michelle Verina
Public Relations
561-922-5808 Ext. 100
[email protected]

September 24, 2012

Boca Raton, FL

Sensus Healthcare is pleased to announce its attendance at the 2012 Fall Clinical Dermatology Conference at The Encore Hotel, Las Vegas, NV on October 4 - 7, 2012. Sensus will be demonstrating its advanced superficial radiotherapy platform, the SRT-100™ for the non- invasive treatment of skin cancer. Sensus will also present an entire deck of case studies from its user base, that demonstrate the efficacy and advantages their SRT-100™ solution provides the patients, physicians, and the healthcare system.

“We are thrilled to participate in the 2012 Fall Clinical Dermatology Conference, where we have the opportunity to meet with the thought leaders in Dermatology,” stated Joe Sardano, President/CEO, Sensus Healthcare. “Our objective at these meetings is to better understand the needs of the physicians and their patients and to demonstrate how the SRT-100™ compliments and fits those needs,” continued, Steve Cohen, Senior Vice President, Strategic Initiatives.

 

About Sensus Healthcare:

Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings.

 

Media Contact:
Michelle Verina
Public Relations
561-922-5808 Ext. 100

May 23, 2011

Boca Raton, FL

Sensus Healthcare is pleased to have exhibited at the 86th National Congress of SIDeMaST (The Italian Society of Dermatology) in Verona, Italy, May 18th – May 21st. Sensus Healthcare featured its SRT-100™ non-surgical, superficial photon therapy system for non-melanoma skin cancers. This year’s event was considered an important national event, representative of the Italian dermatology community. The conference provided 25 courses with CME (Continuing Medical Education), sessions with graduate pro-diagnosed cases, a course for nurses, various symposia of affiliated companies, and sessions devoted to clinical cases and open communications. In total there were approximately 227 readings preordained, 87 communications and 121 posters. The abstracts will be published in print as well as available online in a supplement to the Italian Journal of Dermatology.

Featured in the abstracts is a piece titled, “Back to the Future with Photon Superficial Radiation Therapy for Non-Melanoma Skin Cancer,” written by Domenico Valente, MD, FAAD, Armand B. Cognetta, Jr., MD, and Angela M. Abbatecola, BS, MD, PhD. (Sensus Healthcare Medical Advisory Board Members).

"This conference demonstrated that the challenges that Dermatologists face are similar throughout the world and that the SRT-100™ can provide many solutions to those challenges. It's clear that surgery is not the exclusive answer to treating skin cancers. Photon X-Ray treatment is a great & effective alternative.” –Joe Sardano, CEO of Sensus Healthcare

About Sensus Healthcare:

Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. We also offer a professional skin care line, Sensus Skin Solutions™, through our physician SRT-100™ users for their patients.

Media Contact:

Vicky Perez
Public Relations
561-922-5808 Ext 108
[email protected]

January 24, 2011

Boca Raton, FL

Sensus Healthcare is proud to announce their exhibitor participation in the 69th Annual American Academy of Dermatology Meeting in New Orleans, LA on February 4-8, 2011. Visit booth #3921 to learn about the SRT-100™ low-dose non-invasive superficial radiotherapy (SRT) non-melanoma skin cancer therapy product line, the Sensus Skin Solutions™ professional skin care cosmetics line featuring innovative natural skin care and protection products for daily use, and the Astrum™ EHR (Electronic Healthcare Records) product line for total and seamless practice automation and compliance with the HITECH (Health Information Technology for Economic and Clinical Health bill, signed into law on February 17, 2009) act and incentive plan.

“Sensus cordially invites all AAD attendees to take this opportunity to visit our booth and rediscover non-invasive non-melanoma skin cancer treatment with excellent clinical and cosmetic outcomes. We are very excited to launch two new product lines at the 69th AAD meeting. The first product is our innovative Sensus Skin Solutions™ professional cosmetics line that will be offered by our physician and practitioner partners. Our professional skin care line is an all-natural and innovative collection of cosmetic products that provide excellent protection from the damaging effects of the sun and also a comprehensive array of products to maintain a healthy and beautiful skin. Another exciting product we are launching at the meeting is a state-of-the-art EHR product – the Astrum™ EHR, which is truly unique and innovative in the field of electronic healthcare records. We have identified an unanswered need in the dermatology space for a cost-effective and cohesive solution and we believe that Astrum™ EHR meets and exceeds this need.” –Joe Sardano (Chief Executive Officer, Sensus Healthcare)

Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. We also offer a professional skin care line, Sensus Skin Solutions™, through our physician SRT-100™ users for their patients, and our state-of-the-art Astrum™ EHR true cloud-based solution.

 

For additional information, please contact:
Vicky Perez
Public Relations
[email protected]
561-922-5808 Ext 108

November 2, 2010

San Diego, CA

A new technology company committed to providing a viable treatment option for millions of skin cancer sufferers unveiled a re-design of its signature system this week at the American Society for Radiation Oncology (ASTRO) Annual Conference. ASTRO is the largest radiation oncology society in the world, with more than 10,000 members.

Sensus Healthcare is now showing the newly redesigned SRT-100™, which offers improved mobility features and a streamlined look. The SRT-100™ is powered with a standard electrical outlet.

The SRT-100™ design revisions do not affect the core system, which is cleared by the FDA, UL and has ISO/CE Mark certification. The Sensus Healthcare SRT-100™ is the only system of its kind available in the U.S. to treat non-melanoma skin cancers, and is now in use worldwide.

The SRT-100™ treats basal cell and squamous cell skin cancers, especially those requiring difficult or extensive surgery with sensitive areas in the head and neck regions - the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear - that would otherwise lead to a less than desirable cosmetic outcome. The SRT-100™ treatment procedure does not require the use of anesthetics or skin grafting.

“The Sensus Healthcare treatment option is in no way intended to replace Mohs surgery, which is the standard surgical treatment option for skin cancer patients and an absolute necessity in many cases,” Sensus Chief Executive Officer Joe Sardano said. “However, when surgery is not essential, Sensus offers a viable alternative, one that uses safe and effective low-energy radiotherapy to treat non-melanoma skin cancers. It is a non-invasive process for millions of skin cancer sufferers worldwide.”

“Many skin cancer patients may not even know that they have treatment options beyond surgery, which can lead to scarring and infection,” Sensus Healthcare Chief Operating Officer Kal Fishman added. “Part of the process is educating the public that there are other ways to treat certain types of skin cancer - particularly around the face and neck, where four in five skin cancer cases develop.”

 Sensus Healthcare will also exhibit the SRT-100™ at the 2011 American Academy of Dermatology Annual Meeting in New Orleans on February 4-8.

 

About SENSUS Healthcare - Taking new aim at skin cancer, Sensus Healthcare is focused on the design, manufacture and marketing of products and services that incorporate proprietary mobile X-ray technology for cost-effective, non-invasive treatment of non-melanoma skin cancers. The signature Sensus Healthcare product, the SRT-100™, meets stringent safety requirements set by the FDA, UL and ISO/CE Mark certification. Based in Boca Raton, Fla., Sensus employs best-practice standard operational procedures to ensure quality control, high-grade customer support, optimized success in field operations, and product reliability. For more information, visit www.sensushealthcare.com.

 
Sensus Healthcare Inquiries:
Chris Lato
[email protected]
Office: 262.953.4272
Cell: 608.219.7231

Start your journey to a happy & healthy recovery.
Or search for a treatment location:
Begin Search
FIND A TREATMENT LOCATION
©Copyright 2022 - Sensus Healthcare - All Rights Reserved.
link